- Home
- LUCD vs RDIB Comparison
LUCD vs RDIB Comparison
Compare LUCD & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- RDIB
- Stock Information
- Founded
- LUCD 2018
- RDIB 1937
- Country
- LUCD United States
- RDIB United States
- Employees
- LUCD 70
- RDIB N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RDIB Movies/Entertainment
- Sector
- LUCD Health Care
- RDIB Consumer Discretionary
- Exchange
- LUCD Nasdaq
- RDIB Nasdaq
- Market Cap
- LUCD 135.6M
- RDIB 140.2M
- IPO Year
- LUCD 2021
- RDIB N/A
- Fundamental
- Price
- LUCD $1.19
- RDIB $11.01
- Analyst Decision
- LUCD Strong Buy
- RDIB
- Analyst Count
- LUCD 4
- RDIB 0
- Target Price
- LUCD $3.88
- RDIB N/A
- AVG Volume (30 Days)
- LUCD 1.3M
- RDIB 5.5K
- Earning Date
- LUCD 05-14-2025
- RDIB 05-19-2025
- Dividend Yield
- LUCD N/A
- RDIB N/A
- EPS Growth
- LUCD N/A
- RDIB N/A
- EPS
- LUCD N/A
- RDIB N/A
- Revenue
- LUCD $4,346,000.00
- RDIB $210,527,000.00
- Revenue This Year
- LUCD $107.75
- RDIB $9.74
- Revenue Next Year
- LUCD $231.37
- RDIB $6.39
- P/E Ratio
- LUCD N/A
- RDIB N/A
- Revenue Growth
- LUCD 79.00
- RDIB N/A
- 52 Week Low
- LUCD $0.63
- RDIB $5.78
- 52 Week High
- LUCD $1.80
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- LUCD 40.89
- RDIB 55.42
- Support Level
- LUCD $1.19
- RDIB $11.30
- Resistance Level
- LUCD $1.24
- RDIB $13.35
- Average True Range (ATR)
- LUCD 0.07
- RDIB 1.41
- MACD
- LUCD -0.00
- RDIB -0.05
- Stochastic Oscillator
- LUCD 10.53
- RDIB 33.45
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.